Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer

Sokbom Kang; Woong Ju; Weon Kim Jae; Noh Hyun Park; Yong Sang Song; Cheol Kim Seung; Sang Yoon Park; Soon Beom Kang; Hyo Pyo Lee

doi:10.1038/emm.2006.38

Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer

Sokbom Kang, Woong Ju, Weon Kim Jae, Noh Hyun Park, Yong Sang Song, Cheol Kim Seung, Sang Yoon Park, Soon Beom Kang, Hyo Pyo Lee

Department of Obstetrics and Gynecology

Research output: Contribution to journal › Article › peer-review

82 Scopus citations

Abstract

ERCC1 is a DNA repair gene and has been associated with resistance to DNA damaging agents. In this study we hypothesized that a polymorphism of ERCC1 Asn118Asn (C→T) might affect the platinum-resistance of epithelial ovarian cancer patients to platinum-taxane chemotherapy administered postoperatively. Using the SNapShot assay, we assessed this polymorphism in ERCC1 in 60 ovarian cancer patients. Platinum-resistance was defined as progression on platinum-based chemotherapy or recurrence within 6 months of completing therapy. Although not significant, platinum-resistance was less frequently observed in patients with the C/T + T/T genotype (P = 0.064). Multivariate analysis showed that the C/T + T/T genotypes constituted an independent predictive factor of reduced risk of platinum-resistance in ovarian cancer (odds ratio 0.17, 95% confidence interval 0.04-0.74, P = 0.018, Fisher's exact test). No significant correlation was observed between overall survival and the ERCC1 polymorphism. Our results suggest that genotyping of the ERCC1 polymorphism Asn118Asn may be useful for predicting the platinum-resistance of epithelial ovarian cancer patients. However, these findings require prospective confirmation.

Original language	English
Pages (from-to)	320-324
Number of pages	5
Journal	Experimental and Molecular Medicine
Volume	38
Issue number	3
DOIs	https://doi.org/10.1038/emm.2006.38
State	Published - 30 Jun 2006

Keywords

DNA repair
Drug resistance, neoplasm
ERCC1 protein, human
Ovarian neoplasms
Polymorphism, single nucleotide

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/emm.2006.38

Cite this

Kang, S., Ju, W., Jae, W. K., Park, N. H., Song, Y. S., Seung, C. K., Park, S. Y., Kang, S. B., & Lee, H. P. (2006). Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Experimental and Molecular Medicine, 38(3), 320-324. https://doi.org/10.1038/emm.2006.38

@article{7e99d9d1e7424645889bb9c7f5d869d6,

title = "Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer",

abstract = "ERCC1 is a DNA repair gene and has been associated with resistance to DNA damaging agents. In this study we hypothesized that a polymorphism of ERCC1 Asn118Asn (C→T) might affect the platinum-resistance of epithelial ovarian cancer patients to platinum-taxane chemotherapy administered postoperatively. Using the SNapShot assay, we assessed this polymorphism in ERCC1 in 60 ovarian cancer patients. Platinum-resistance was defined as progression on platinum-based chemotherapy or recurrence within 6 months of completing therapy. Although not significant, platinum-resistance was less frequently observed in patients with the C/T + T/T genotype (P = 0.064). Multivariate analysis showed that the C/T + T/T genotypes constituted an independent predictive factor of reduced risk of platinum-resistance in ovarian cancer (odds ratio 0.17, 95% confidence interval 0.04-0.74, P = 0.018, Fisher's exact test). No significant correlation was observed between overall survival and the ERCC1 polymorphism. Our results suggest that genotyping of the ERCC1 polymorphism Asn118Asn may be useful for predicting the platinum-resistance of epithelial ovarian cancer patients. However, these findings require prospective confirmation.",

keywords = "DNA repair, Drug resistance, neoplasm, ERCC1 protein, human, Ovarian neoplasms, Polymorphism, single nucleotide",

author = "Sokbom Kang and Woong Ju and Jae, {Weon Kim} and Park, {Noh Hyun} and Song, {Yong Sang} and Seung, {Cheol Kim} and Park, {Sang Yoon} and Kang, {Soon Beom} and Lee, {Hyo Pyo}",

year = "2006",

month = jun,

day = "30",

doi = "10.1038/emm.2006.38",

language = "English",

volume = "38",

pages = "320--324",

journal = "Experimental and Molecular Medicine",

issn = "1226-3613",

publisher = "Korean Society of Med. Biochemistry and Mol. Biology",

number = "3",

}

Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. / Kang, Sokbom; Ju, Woong; Jae, Weon Kim et al.
In: Experimental and Molecular Medicine, Vol. 38, No. 3, 30.06.2006, p. 320-324.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer

AU - Kang, Sokbom

AU - Ju, Woong

AU - Jae, Weon Kim

AU - Park, Noh Hyun

AU - Song, Yong Sang

AU - Seung, Cheol Kim

AU - Park, Sang Yoon

AU - Kang, Soon Beom

AU - Lee, Hyo Pyo

PY - 2006/6/30

Y1 - 2006/6/30

N2 - ERCC1 is a DNA repair gene and has been associated with resistance to DNA damaging agents. In this study we hypothesized that a polymorphism of ERCC1 Asn118Asn (C→T) might affect the platinum-resistance of epithelial ovarian cancer patients to platinum-taxane chemotherapy administered postoperatively. Using the SNapShot assay, we assessed this polymorphism in ERCC1 in 60 ovarian cancer patients. Platinum-resistance was defined as progression on platinum-based chemotherapy or recurrence within 6 months of completing therapy. Although not significant, platinum-resistance was less frequently observed in patients with the C/T + T/T genotype (P = 0.064). Multivariate analysis showed that the C/T + T/T genotypes constituted an independent predictive factor of reduced risk of platinum-resistance in ovarian cancer (odds ratio 0.17, 95% confidence interval 0.04-0.74, P = 0.018, Fisher's exact test). No significant correlation was observed between overall survival and the ERCC1 polymorphism. Our results suggest that genotyping of the ERCC1 polymorphism Asn118Asn may be useful for predicting the platinum-resistance of epithelial ovarian cancer patients. However, these findings require prospective confirmation.

AB - ERCC1 is a DNA repair gene and has been associated with resistance to DNA damaging agents. In this study we hypothesized that a polymorphism of ERCC1 Asn118Asn (C→T) might affect the platinum-resistance of epithelial ovarian cancer patients to platinum-taxane chemotherapy administered postoperatively. Using the SNapShot assay, we assessed this polymorphism in ERCC1 in 60 ovarian cancer patients. Platinum-resistance was defined as progression on platinum-based chemotherapy or recurrence within 6 months of completing therapy. Although not significant, platinum-resistance was less frequently observed in patients with the C/T + T/T genotype (P = 0.064). Multivariate analysis showed that the C/T + T/T genotypes constituted an independent predictive factor of reduced risk of platinum-resistance in ovarian cancer (odds ratio 0.17, 95% confidence interval 0.04-0.74, P = 0.018, Fisher's exact test). No significant correlation was observed between overall survival and the ERCC1 polymorphism. Our results suggest that genotyping of the ERCC1 polymorphism Asn118Asn may be useful for predicting the platinum-resistance of epithelial ovarian cancer patients. However, these findings require prospective confirmation.

KW - DNA repair

KW - Drug resistance, neoplasm

KW - ERCC1 protein, human

KW - Ovarian neoplasms

KW - Polymorphism, single nucleotide

UR - http://www.scopus.com/inward/record.url?scp=33745830472&partnerID=8YFLogxK

U2 - 10.1038/emm.2006.38

DO - 10.1038/emm.2006.38

M3 - Article

C2 - 16819291

AN - SCOPUS:33745830472

SN - 1226-3613

VL - 38

SP - 320

EP - 324

JO - Experimental and Molecular Medicine

JF - Experimental and Molecular Medicine

IS - 3

ER -

Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this